Bracco release confirms Positron's market growth prediction of cardiac PET

Jun 19 2010

Positron Corporation (OTCBB:POSC), a leader as a molecular imaging and solutions company specializing in the field of Nuclear Cardiology, cites an article posted on AuntMinnie.com, the largest community website for medical imaging professionals, relating to the growth in cardiac PET.

“The Bracco release further confirms our market growth prediction. We are seeing an unprecedented request for proposals and look forward to meeting the increasing demand.”

Contrast agent developer Bracco Diagnostics said that the number of customers using its CardioGen-82 cardiac PET myocardial perfusion imaging (MPI) tracer has increased by 46% in comparison with June of 2009.

The Princeton, NJ-based vendor attributed the growth to increasing momentum for cardiac PET, publication of key clinical data, improvements in PET hardware/software technology and accessibility, and expanding society and academic advocacy for MPI.

Joseph Oliverio, Chief Technology Officer of Positron states, "The Bracco release further confirms our market growth prediction. We are seeing an unprecedented request for proposals and look forward to meeting the increasing demand."

SOURCE Positron Corporation